Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer

This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.

Trial Details

NCT ID
NCT06406660
Phase
NA
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Age ≥18 and ≤75 years old (calculated based on the date of signing informed consent);
  • Diagnosed as recurrent small cell lung cancer;
  • After at least one systematic treatment and the disease progresses;
  • According to the efficacy evaluation criteria of solid tumors (RECIST 1.1), at least one lesion that has not received radiation therapy, has not re…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →